nivolumab,ipilimumab
bms
[]
 nivo + ctx vs ctx as 1l therapy for #gastroesophagealcancers
@ asco-gi 2023 3-yr follow-up checkmate 649, cps 5 mos: 14.4 vs 11.1, mss 13.9 vs 11.5 mpfs: 8.3 vs 6.1 mo orr: 60% vs 45% dor: 9.6 vs 7 mo meaningful long-term survival benefit 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision medicine